BioCentury
ARTICLE | Company News

Roche gets option to Ionis' antisense dry AMD candidate

October 12, 2018 6:05 PM UTC

Roche (SIX:ROG; OTCQX:RHHBY) will pay Ionis Pharmaceuticals Inc. (NASDAQ:IONS) $75 million up front for an option to develop and commercialize IONIS-FB-LRx, a ligand-conjugated antisense (LICA) oligonucleotide targeting complement factor B (CFB).

The partners plan to develop the candidate for complement-mediated diseases, with an initial focus on geographic atrophy, the advanced stage of dry age-related macular degeneration (AMD)...

BCIQ Company Profiles

Ionis Pharmaceuticals Inc.

Roche